Take a look at our previous reports:

Forward with
Purpose


Annual Report 2022

scroll for more
Letter from
the CEO and Chairman

2022 was characterized by major transformation and change but our purpose remains unchanged: transforming patient outcomes through life-changing science and innovation for more years of life and quality of life.

Dr. Paul Stoffels, CEO and Chairman

Financial highlights

Group net revenues
505.3
million
Cash position
4094.1
million
Deferred income
1989.2
million
R&D expenditure
515.1
million

Features

Key Events in 2022

Dash-board

Magazine

Leading the way

Annelies Missotten, Chief Human Resources Officer and Valeria Cnossen, General Counsel, are the newest executive members of the Galapagos Management Committee. What is their view on leadership?

The future of CAR-T at point-of-care

We believe that real differentiation and access to therapy can come from a disruptive decentralized CAR-T manufacturing model at point-of-care, close to patients, combined with innovative science and expert teams.

Living with RA and UC

Heidi, Mireille and Garry share their experience about living with immunological diseases, rheumatoid arthritis (RA) and ulcerative colitis (UC). Three stories about getting through the day the best way possible.